| Arbutus Biopharma is a biopharmaceutical company focused on developing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (HBV). Co. is developing a product pipeline consisting of multiple drug candidates with complementary mechanisms of action. Co.'s pipeline includes: AB-729, a subcutaneously-delivered RNA interference therapeutic product candidate; AB-836, a capsid inhibitor product candidate; and other compounds early in the development process, including back-up capsid inhibitors, oral HBV RNA destabilizers and compounds that inhibit PD-L1. We show 43 historical shares outstanding datapoints in our ABUS shares outstanding history coverage, used to compute ABUS market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ABUS market cap history over the course of time is important for investors
interested in comparing ABUS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ABUS versus a peer is one thing; comparing
ABUS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ABUS can fluctuate over the course of history.
With this page we aim to empower investors researching ABUS by allowing them to research the ABUS market cap history.